Effect of GLP-1 on Lipid Metabolism in Human Adipocytes
The DOI matches its Crossref record.
Abstract
We have studied the effect of several doses of GLP-1, compared to that of insulin and glucagons, on lipogenesis, lipolysis and cAMP cellular content, in human adipocytes isolated from normal subjects. In human adipocytes, GLP-1 exerts a dual action, depending upon the dose, on lipid metabolism, being lipogenic at low concentrations of the peptide (ED50, 10(-12) M), and lipolytic only at doses 10-100 times higher (ED50, 10(-10) M); both effects are time- and GLP-1 concentration-dependent. The GLP-1 lipogenic effect is equal in magnitude to that of equimolar amounts of insulin; both hormones apparently act synergically, and their respective action is abolished by glucagon. The lipolytic effect of GLP-1 is comparable to that of glucagon, apparently additive to it, and the stimulated value induced by either one is neutralized by the presence of insulin. In the absence of IBMX, GLP-1, at 10(-13) and 10(-12) M, only lipogenic doses, does not modify the cellular content of cAMP, while from 10(-11) M to 10(-9) M, also lipolytic concentrations, it has an increasing effect; in the presence of IBMX, GLP-1 at already 10(-12) M increased the cellular cAMP content. In human adipocytes, GLP-1 shows glucagon- and also insulin-like effects on lipid metabolism, suggesting the possibility of GLP-1 activating two distinct receptors, one of them similar or equal to the pancreatic one, accounting cAMP as a second messenger only for the lipolytic action of the peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“According to experimental research, GLP-1 can certainly cause both lipogenic and lipolytic effects in a dose-dependent manner, with lipogenic action predominating at picomolar concentrations and lipolytic action at nanomolar doses [59,60,61,62,63].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [61]
Citations
Cites
Still being checked.
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
Armstrong, M. J., Hull, D., Guo, K., Barton, D., Hazlehurst, J. M., Gathercole, L. L., Nasiri, M., Yu, J., Gough, S. C., Newsome, P. N., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.08.038 · Cited by 456
“A direct action of GLP-1 to regulate lipolysis in the absence of insulin has not been a consistent in vitro finding and may reflect variations in dosage and culture conditions [35–37].”
BackgroundThomsen, C., Storm, H., Holst, J. J., & Hermansen, K. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.3.605 · Cited by 221
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Nuche-Berenguer, B., Moreno, P., Esbrit, P., Dapía, S., Caeiro, J. R., Cancelas, J., Haro-Mora, J. J., & Villanueva-Peñacarrillo, M. L. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9220-3 · Cited by 192
Self-citationGLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189
The Gut-Brain Axis, the Human Gut Microbiota and Their Integration in the Development of Obesity
Bliss, E. S., & Whiteside, E. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00900 · Cited by 186
Nogueiras, R., Pérez-Tilve, D., Veyrat-Durebex, C., Morgan, D. A., Varela, L., Haynes, W. G., Patterson, J. T., Disse, E., Pfluger, P. T., López, M., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5977-08.2009 · Cited by 182
“…that GLP-1 can directly act on adipocyte metabolism, although the molecular mechanisms modulating those peripheral actions are unknown (Ruiz-Grande et al., 1992; Mérida et al., 1993; Valverde et al., 1993; Bertin et al., 2001; Villanueva-Peñacarrillo et al., 2001; Sancho et al., 2005, 2006).”
BackgroundRomaní-Pérez, M., Outeiriño-Iglesias, V., Moya, C. M., Santisteban, P., González-Matías, L. C., Vigo, E., & Mallo, F. (2015) · Endocrinology · doi:10.1210/en.2014-1685 · Cited by 178
Vendrell, J., El Bekay, R., Peral, B., García-Fuentes, E., Megia, A., Macias-Gonzalez, M., Real, J. F., Jimenez-Gomez, Y., Escoté, X., Pachón, G., et al. (2011) · Endocrinology · doi:10.1210/en.2011-1070 · Cited by 173
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.03.012 · Cited by 168
KOŁODZIEJSKI, P. A., PRUSZYŃSKA-OSZMAŁEK, E., KOREK, E., SASSEK, M., SZCZEPANKIEWICZ, D., KACZMAREK, P., NOGOWSKI, L., MAĆKOWIAK, P., NOWAK, K. W., KRAUSS, H., et al. (2018) · Physiological Research · doi:10.33549/physiolres.933467 · Cited by 128
Gunnarsson, P. T., Winzell, M. S., Deacon, C. F., Larsen, M. O., Jelic, K., Carr, R. D., & Ahrén, B. (2006) · Endocrinology · doi:10.1210/en.2005-1442 · Cited by 129
Boschmann, M., Engeli, S., Dobberstein, K., Budziarek, P., Strauss, A., Boehnke, J., Sweep, F. C. G. J., Luft, F. C., He, Y., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1400 · Cited by 110
Metabolic surgery and gut hormones – A review of bariatric entero-humoral modulation
Ashrafian, H., & le Roux, C. W. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.03.012 · Cited by 113
GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia
Nuche-Berenguer, B., Lozano, D., Gutiérrez-Rojas, I., Moreno, P., Mariñoso, M. L., Esbrit, P., & Villanueva-Peñacarrillo, M. L. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0015 · Cited by 96
Self-citationExendin-4 Potently Decreases Ghrelin Levels in Fasting Rats
Pérez-Tilve, D., González-Matías, L., Alvarez-Crespo, M., Leiras, R., Tovar, S., Diéguez, C., & Mallo, F. (2007) · Diabetes · doi:10.2337/db05-0996 · Cited by 92
Effect of GLP-1 on glucose transport and its cell signalling in human myocytes
González, N., Acitores, A., Sancho, V., Valverde, I., & Villanueva-Peñacarrillo, M. L. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.10.002 · Cited by 85
Self-citationEffects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes
El Bekay, R., Coín‐Aragüez, L., Fernández‐García, D., Oliva‐Olivera, W., Bernal‐López, R., Clemente‐Postigo, M., Delgado‐Lista, J., Diaz‐Ruiz, A., Guzman‐Ruiz, R., Vázquez‐Martínez, R., et al. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13481 · Cited by 78
Sancho, V., Trigo, M. V., González, N., Valverde, I., Malaisse, W. J., & Villanueva-Peñacarrillo, M. L. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01747 · Cited by 78
“…(Morales et al. 1997, López-Delgado et al. 1998) states; in addition, this incretin (Creutzfeldt 2001) modulates the glucose transporter levels in 3T3-L1 adipocytes (Wang et al. 1997) and in liver, fat tissue and skeletal muscle of normal and diabetic rats (Villanueva-Peñacarrillo et al. 2001b).”
BackgroundSelf-citationA Systematic Review and Meta-analysis of the Effect of Gastric Bypass Surgery on Plasma Lipid Levels
Carswell, K. A., Belgaumkar, A. P., Amiel, S. A., & Patel, A. G. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1829-x · Cited by 94
Zaïmia, N., Obeid, J., Varrault, A., Sabatier, J., Broca, C., Gilon, P., Costes, S., Bertrand, G., & Ravier, M. A. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113326 · Cited by 89
Buhmann, H., le Roux, C. W., & Bueter, M. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.003 · Cited by 102
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Mechanisms of Disease: the role of gastrointestinal hormones in appetite and obesity
Vincent, R. P., Ashrafian, H., & le Roux, C. W. (2008) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep1118 · Cited by 75
Unraveling the Science of Incretin Biology
Nauck, M. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.012 · Cited by 72
de Carvalho, C. P., Marin, D. M., de Souza, A. L., Pareja, J. C., Chaim, É. A., de Barros-Mazon, S., da Silva, C. A., Geloneze, B., Muscelli, E., & Alegre, S. M. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9678-5 · Cited by 64
Dietary Effects on Incretin Hormone Secretion
Wu, T., Rayner, C. K., Jones, K. L., & Horowitz, M. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00003-5 · Cited by 62
Marrano, N., Biondi, G., Borrelli, A., Cignarelli, A., Perrini, S., Laviola, L., Giorgino, F., & Natalicchio, A. (2021) · Biomolecules · doi:10.3390/biom11020286 · Cited by 56
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin
Åhrén, B., Foley, J. E., & Bosi, E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01321.x · Cited by 64
He, M., Su, H., Gao, W., Johansson, S. M., Liu, Q., Wu, X., Liao, J., Young, A. A., Bartfai, T., & Wang, M.-W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014205 · Cited by 56
Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle
Acitores, A., Gonzalez, N., Sancho, V, Valverde, I., & Villanueva-Penacarrillo, M. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800389 · Cited by 55
Self-citationA role of PLC/PKC-dependent pathway in GLP-1-stimulated insulin secretion
Shigeto, M., Cha, C. Y., Rorsman, P., & Kaku, K. (2017) · Journal of Molecular Medicine · doi:10.1007/s00109-017-1508-6 · Cited by 59
Nie, Y., Ma, R. C., Chan, J. C. N., Xu, H., & Xu, G. (2012) · The FASEB Journal · doi:10.1096/fj.11-196782 · Cited by 53
Ejarque, M., Guerrero-Pérez, F., de la Morena, N., Casajoana, A., Virgili, N., López-Urdiales, R., Maymó-Masip, E., Pujol Gebelli, J., Garcia Ruiz de Gordejuela, A., Perez-Maraver, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-42770-1 · Cited by 53
Effect of GLP-1 on D-glucose transport, lipolysis and lipogenesis in adipocytes of obese subjects
Sancho, V., Trigo, M., Martín-Duce, A., González, N., Acitores, A., Arnés, L., Valverde, I., Malaisse, W., & Villanueva-Peñacarrillo, M. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.6.1133 · Cited by 53
Self-citationShimasaki, T., Masaki, T., Mitsutomi, K., Ueno, D., Gotoh, K., Chiba, S., Kakuma, T., & Yoshimatsu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063626 · Cited by 52
Romaní-Pérez, M., Outeiriño-Iglesias, V., Gil-Lozano, M., González-Matías, L. C., Mallo, F., & Vigo, E. (2013) · Endocrinology · doi:10.1210/en.2012-1786 · Cited by 51
“Ex4 and Lir ([Lys ( -Glu-palmitoyl)]-GLP-1 [7-37]) were purchased from Bachem (Bubendorf, Switzerland), whereas dexamethasone (Dex) was supplied by Merck (Madrid, Spain) and nitrofen (NTF) (2,4-dichloro-4 -nitrophenyl ether) by Sigma (St Louis, Missouri).”
MethodCeddia, R. P., & Collins, S. (2020) · Clinical Science · doi:10.1042/cs20190579 · Cited by 53
Martins, A. D., Monteiro, M. P., Silva, B. M., Barros, A., Sousa, M., Carvalho, R. A., Oliveira, P. F., & Alves, M. G. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.10.009 · Cited by 55
Ugleholdt, R., Pedersen, J., Bassi, M. R., Füchtbauer, E.-M., Jørgensen, S. M., Kissow, H.-L., Nytofte, N., Poulsen, S. S., Rosenkilde, M. M., Seino, Y., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.311779 · Cited by 49
Circulating Levels of Ghrelin and GLP-1 are Inversely Related During Glucose Ingestion
Djurhuus, C., Hansen, T. K., Gravholt, C. H., Ørskov, L., Hosoda, H., Kangawa, K., Jørgensen, J. O. L., Holst, J. J., & Schmitz, O. (2002) · Hormone and Metabolic Research · doi:10.1055/s-2002-33475 · Cited by 46
Petrovic, A., Igrec, D., Rozac, K., Bojanic, K., Kuna, L., Kolaric, T. O., Mihaljevic, V., Sikora, R., Smolic, R., Glasnovic, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45060288 · Cited by 41
“Evidence supports a role for GLP-1 as a regulator of lipid and lipoprotein metabolism, even the possibility that GLP-1 may activate two distinct receptors, with one of them being similar or equivalent to the pancreatic receptor and the second one responsible for its lipolytic effects [44,45].”
BackgroundEngeli, S., Stinkens, R., Heise, T., May, M., Goossens, G. H., Blaak, E. E., Havekes, B., Jax, T. W., Albrecht, D., Pal, P., et al. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.10224 · Cited by 44
Lavu, M. S., Porto, J. R., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.06.008 · Cited by 47
Sancho, V., Nuche, B., Arnés, L., Cancelas, J., Gonz´lez, N., Díaz-Miguel, M., Martín-Duce, A., Valverde, I., & Villanueva-Peñacarrillo, M. (2007) · International Journal of Molecular Medicine · doi:10.3892/ijmm.19.6.961 · Cited by 40
Self-citationGLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
Liu, C., Hu, M., Zhang, M., Li, F., Li, J., Zhang, J., Li, Y., Guo, H., Xu, P., Liu, L., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.015 · Cited by 38
Calanna, S., Piro, S., Pino, A. D., Zagami, R. M., Urbano, F., Purrello, F., & Rabuazzo, A. M. (2013) · Obesity · doi:10.1002/oby.20017 · Cited by 39
Maciel, M. G., Beserra, B. T. S., Oliveira, F. C. B., Ribeiro, C. M., Coêlho, M. S., Neves, F. D. A. R., & Amato, A. A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.034 · Cited by 40
Mechanisms of Weight Loss after Gastric Bypass and Gastric Banding
Bueter, M., Ashrafian, H., & le Roux, C. W. (2009) · Obesity Facts · doi:10.1159/000232383 · Cited by 35
Shigeto, M., Katsura, M., Matsuda, M., Ohkuma, S., & Kaku, K. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08090fp · Cited by 33
Rizzo, M., Nikolić, D., Banach, M., Giglio, R. V., Patti, A. M., Bartolo, V. D., Tamburello, A., Zabbara, A., Pecoraro, G., Montalto, G., et al. (2013) · Clinical Lipidology · doi:10.2217/clp.13.8 · Cited by 34
Åkesson, L., Åhrén, B., Manganiello, V. C., Holst, L. S., Edgren, G., & Degerman, E. (2003) · Endocrinology · doi:10.1210/en.2003-0364 · Cited by 33
Dalgaard, M., Thomsen, C., Rasmussen, B. M., Holst, J. J., & Hermansen, K. (2003) · Metabolism · doi:10.1016/j.metabol.2003.08.011 · Cited by 34
Oliveira, F. C. B., Bauer, E. J., Ribeiro, C. M., Pereira, S. A., Beserra, B. T. S., Wajner, S. M., Maia, A. L., Neves, F. A. R., Coelho, M. S., & Amato, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.803363 · Cited by 30
“Indeed, data from cell-based studies indicate direct effects of GLP-1 on adipocytes, such as adipogenesis induction (5) and activation of both lipogenesis and lipolysis dependent upon GLP-1/GLP-1A concentration (34, 35).”
BackgroundPorto, J. R., Lavu, M. S., Hecht, C. J., Kaelber, D. C., Sculco, P. K., Heckmann, N. D., & Kamath, A. F. (2025) · Orthopaedic Journal of Sports Medicine · doi:10.1177/23259671241297157 · Cited by 38
The Impact of Incretin-Based Medications on Lipid Metabolism
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1815178 · Cited by 33
Glucagon resistance and metabolic-associated steatotic liver disease: a review of the evidence
McGlone, E. R., Bloom, S. R., & Tan, T. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0365 · Cited by 30
Wahl, S., Krug, S., Then, C., Kirchhofer, A., Kastenmüller, G., Brand, T., Skurk, T., Claussnitzer, M., Huth, C., Heier, M., et al. (2013) · Metabolomics · doi:10.1007/s11306-013-0586-x · Cited by 28
Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients
Villanueva‐Peñacarrillo, M. L., Martín‐Duce, A., Ramos-Álvarez, I., Gutiérrez-Rojas, I., Moreno, P., Nuche‐Berenguer, B., Acitores, A., Sancho, V., Valverde, I., & González, N. (2011) · Regulatory Peptides · doi:10.1016/j.regpep.2011.03.002 · Cited by 31
Self-citationHormonal Regulation of Lipogenesis
Gathercole, L., Morgan, S., & Tomlinson, J. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00001-8 · Cited by 31
Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats
Model, J. F. A., Lima, M. V., Ohlweiler, R., Vogt, É. L., Rocha, D. S., de Souza, S. K., Türck, P., Araújo, A. S. D. R., & Vinagre, A. S. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111158 · Cited by 24
Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus
Nasr, N. E., & Sadek, K. M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-18534-2 · Cited by 32
Heckmann, N. D., Palmer, R. C., Mayfield, C. K., Gucev, G., Lieberman, J. R., & Hong, K. M. (2024) · Arthroplasty Today · doi:10.1016/j.artd.2024.101327 · Cited by 22
Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis
Cignarelli, A., Giorgino, F., & Vettor, R. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.796996 · Cited by 24
Tani, S., Takahashi, A., Nagao, K., & Hirayama, A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.044 · Cited by 19
Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 18
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
Gastrointestinal regulatory peptides and their effects on fat tissue
Majumdar, I. D., & Weber, H. C. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833327dd · Cited by 18
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17
Identification and characterization of adipose surface epitopes
Onogi, Y., Khalil, A., & Ussar, S. (2020) · Biochemical Journal · doi:10.1042/bcj20190462 · Cited by 16
Plasma levels of glucagon‐like peptide 1 and markers of obesity among young and healthy adults
van der Stouwe, J. G., Aeschbacher, S., Krisai, P., Schoen, T., Meyre, P. B., Todd, J., Estis, J., Risch, M., Risch, L., & Conen, D. (2015) · Clinical Endocrinology · doi:10.1111/cen.12789 · Cited by 18
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
“Forever young at the table”: metabolic effects of eating speed in obesity
Barrea, L., Vetrani, C., Verde, L., Napolitano, B., Savastano, S., Colao, A., & Muscogiuri, G. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03199-1 · Cited by 14
Bojanowska, E., & Stempniak, B. (2001) · PubMed · Cited by 15
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, H., Pandey, D., Patel, D. N., Sutariya, B., Patel, M. S., Bahekar, R. H., & Jain, M. R. (2017) · Drug Research · doi:10.1055/s-0043-118808 · Cited by 11
Giorgino, F., Natalicchio, A., Leonardini, A., & Laviola, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.09.022 · Cited by 11
Bueter, M., & le Roux, C. W. (2009) · Proceedings of The Nutrition Society · doi:10.1017/s0029665109001256 · Cited by 10
Brachs, S., Soll, D., Beer, F., Huckauf, N., Konkar, A. A., Spranger, J., Rütten, H., & Mai, K. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae151 · Cited by 7
Duodenal-Jejunal Bypass Restores Insulin Action and Βeta-Cell Function in Hypothalamic-Obese Rats
Bonfleur, M. L., Ribeiro, R. A., Pavanello, A., Soster, R., Lubaczeuski, C., Araújo, A. C. F., Boschero, A. C., & Balbo, S. L. (2014) · Obesity Surgery · doi:10.1007/s11695-014-1427-3 · Cited by 9
Muralikrishnan, A. S., Biasin, V., Zabini, D., & Osto, E. (2025) · Acta Physiologica · doi:10.1111/apha.70091 · Cited by 5
Patel, R., Parmar, N. B., Palit, S. P., RATHWA, N. N., & Begum, R. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02014-6 · Cited by 9
A novel gene therapy platform for the treatment of type 2 diabetes and obesity
Lourie, J., Goraltchouk, A., Hollander, J. M., BERGER, N. J. A., Rosen, H. G., Fujishiro, A. A., Luppino, F., Seregin, A., Rhym, L. H., & Zou, K. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102739 · Cited by 6
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Patel, T., Rose, J., Katsurada, K., Yada, T., Koutakis, P., Salomon, J., Patel, K. P., & Alfaidi, M. (2026) · Circulation Research · doi:10.1161/circresaha.126.327683 · Cited by 4
Mulherin, A. J., Oh, A., Kim, H., Grieco, A., Lauffer, L., & Brubaker, P. (2011) · Obesity and metabolism · doi:10.14341/2071-8713-5305 · Cited by 4
The incretin system in type 2 diabetes mellitus: cardiovascular effects
Sukhareva, O. Y., Шмушкович, И. А., Shestakova, E. A., & Shestakova, M. V. (2013) · Problems of Endocrinology · doi:10.14341/probl201258633-42 · Cited by 6
Meal Duration and Obesity-Related Indicators among Adolescents: Insights from the EHDLA Study
Martínez-López, M. F., & López-Gil, J. F. (2024) · Nutrients · doi:10.3390/nu16162769 · Cited by 3
Cheng, Y., Xie, Y., Sun, W., Chen, C., Li, C., Pérez-López, F. R., Yu, Z., Yang, F., Wang, Y., & Yuan, J. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003894 · Cited by 3
El GLP-1: acción biológica y posibles efectos terapéuticos
Valverde, I., Cancelas, J., & Villanueva-Peñacarrillo, M. (2006) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(06)71100-7 · Cited by 6
Self-citationFalahee, B. E., Apovian, C. M., & Istfan, N. W. (2026) · Obesity · doi:10.1002/oby.70294 · Cited by 2
Inkretine: Gibt es kardiovaskuläre Effekte?
Gallwitz, B. (2010) · Herz · doi:10.1007/s00059-010-3333-3 · Cited by 1
The binding and activation of the glucagon-like peptide-1 receptor by exendin-4
Nasr, E. M. N. (2010) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Ramesh, N. (2015) · University Library - University of Saskatchewan (University of Saskatchewan)
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Ribé, A. A. (2005) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Bojanowska, E., & Stempniak, B. (2003) · Neuroendocrinology · doi:10.1159/000068647
Metadata
- Authors
- Villanueva-Peñacarrillo, M. L., Márquez, L., González, N., Díaz-Miguel*, M., & Valverde, I.
- ORCID
- González, N.
- Venue
- Hormone and Metabolic Research
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 33
- Issue
- 2
- Pages
- 73-77
- ISSN
- 0018-5043 (ISSN-L)
- 1439-4286
- OpenAlex
- W2029102093
- Cited by
- 113
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 5 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 1 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 6
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Hormone and Metabolic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Lipid metabolism and biosynthesis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- glucagon-like peptide-1, human adipocytes, lipid metabolism, lipogenesis, lipolysis, insulin, glucagon, cyclic AMP, dose-dependent effects, hormone synergy, 3-isobutyl-1-methylxanthine, second messengers
- MeSH terms
- Cyclic AMP, Dose-Response Relationship, Drug, Female, Glucagon, Humans, Lipids, Lipolysis, Male, Middle Aged, Peptide Fragments, Protein Precursors, 1-Methyl-3-isobutylxanthine, Adipocytes, Lipid Metabolism, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.